Journal
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Volume 46, Issue 4, Pages 780-783Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jpba.2007.11.013
Keywords
development; validation; mesylate esters; imatimb mesylate
Categories
Ask authors/readers for more resources
A gas chromatography-mass spectrometry (GC-MS) method has been developed for the identification and determination of two carcinogenic and genotoxic mesylate esters viz. methyl methanesulfonate (MMS) and ethyl methanesulfonate (EMS) in imatinib mesylate (INM). The method was optimized based on the peak shapes and resolution of MMS and EMS. The method was validated as per International Conference of Harmonization (ICH) guidelines in terms of limits of detection (LOD), limit of quantitation (LOQ), linearity, precision, accuracy, specificity and robustness. The LOD and LOQ values were found to be 0.3 and 1.0 mu g/ml, respectively. The method is linear within the range of 1-15 mu g/ml for both the compounds. These mesylate esters were not found in three different batches of pure and pharmaceutical formulations of INM. (C) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available